Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose NNC151-0000 in rheumatoid arthritis
2009-011791-30Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing NNC151-0000 multiple-dose with Placebo (2 arms). Primary endpoints: Safety and tolerability (adverse events and toxicity) and Immunogenicity of NNC151-0000. Started Oct 2009; status: completed.
02
Drugs
NNC151-0000
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-011791-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011791-30.